Korro Bio, Inc. (ticker: KRRO) is an NASDAQ-listed pharma company. DredgeCap's structured extraction of KRRO's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. KRRO reported $0 in revenue and -$19.63M for the period ending 2026-03-31, with operating cash flow of -$16.07M. Cash and equivalents stood at $61.70M (down 3.8% year-over-year). Total assets of $183.62M exceed total liabilities of $63.99M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
KRRO Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for Korro Bio, Inc. (KRRO) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.